Global generics industry - enticing opportunities; Report

The global generics industry is doing remarkably well. It is hard to find another sector with similarly favorable structural trends. Generics are the economic answer to spiraling healthcare spending in industrialized countries and they are a direct play on emerging market growth trends, notes a new report from Switzerland-based Bellevue Asset Management.

The sector's next growth catalyst - biosimilars - is already in sight too. These factors are the basis for the generics industry's estimated annual growth rates of 10%. Bellevue's healthcare team has been investing in this particular market segment via a Swiss investment fund since 2008. Now Bellevue has launched a Luxemburg-based fund, BB Adamant Global Generics, with Oliver Kubli as lead portfolio manager.

Healthcare costs have been increasing steadily around the world. That is mainly because of population aging and the growing medical needs associated with elderly cohorts. Improved access to health care services across emerging markets in the wake of rising living standards is also fueling overall expenditure on health care. Therefore there is a general pressure to contain costs in health care systems around the world.